US4908204A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof
Assignee: Beecham Group PLC
•
Filing: 1988-02-22
•
Granted: 1990-03-13
•
Expires: 2008-02-22
Abstract
Abstract A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
Inventors
- 👤 Jeffery H. Robinson
- 👤 Ian Dodd
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:46
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6435; C12N9/6456; C12N9/6459; C12Y; C12Y304/00; C12Y304/21; C12Y304/21007; C12Y304/21069; A; A61; A61K; A61K38/00; C07; C07K; C07K2319/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
50 words
A pharmaceutical composition for treating thrombotic diseases, which comprises an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
Claim 2
Dependent Claim
50 words
A pharmaceutical composition for treating thrombotic diseases, which comprises an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
Claim 3
Dependent Claim
54 words
A pharmaceutical composition for treating thrombotic diseases, which comprise an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and has a catalytic site essential for catalytic activity blocked by a removable blocking group.
Claim 4
Dependent Claim
54 words
A pharmaceutical composition for treating thrombotic diseases, which comprise an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and has a catalytic site essential for catalytic activity blocked by a removable blocking group.
Claim 5
Dependent Claim
17 words
The composition according to claim 2, wherein said removable blocking group is benzoyl or a benzoyl derivative.
Claim 6
Dependent Claim
38 words
The composition according to claim 3, wherein said benzoyl derivative is benzoyl substituted by a substituent selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkanoyloxy, C 1-6 alkanoylamino, amino and p-guanido.
Claim 7
Dependent Claim
47 words
The composition according to claim 1, wherein said protein is selected from the group consisting of 4-aminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain); N-methylaminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain); and N,N-dimethylaminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain).
Claim 8
Independent Claim
48 words
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein comprising plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
Claim 9
Independent Claim
48 words
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein comprising plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
Claim 10
Independent Claim
57 words
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and which has a catalytic site essential for catalytic activity blocked by a removable blocking group.
Claim 11
Independent Claim
57 words
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and which has a catalytic site essential for catalytic activity blocked by a removable blocking group.
Claim 12
Dependent Claim
17 words
The method according to claim 7, wherein said removable blocking group is benzoyl or a benzoyl derivative.
Claim 13
Dependent Claim
38 words
The method according to claim 8, wherein said benzoyl derivative is benzoyl substituted by a substituent selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkanoyloxy, C 1-6 alkanoylamino, amino or p-guanido.
Claim 14
Dependent Claim
47 words
The method according to claim 6, wherein said protein is selected from the group consisting of 4-aminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain); N-methylaminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain); and N,N-dimethylaminobenzoyl (plasmin A-chain covalently linked to tissue plasminogen activator B-chain).
References Cited (Backward Citations)
US4082612A
Cited
EP0009879A1
Cited
US4285932A
Cited
US4507283A
Cited
US4545988A
Cited
EP0155387A2
Cited
US4600580A
Cited
EP0196920A2
Cited
EP0213794A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-12 | 1993-09-11 | 1994-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-12 | 1997-09-11 | 1998-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-12 | 2001-09-11 | 2002-03-13 | $7700.00 | Window Closed / Lapsed |